HIV and ID Observations

November 25th, 2019

Vaccine Defenders, U=U Holds Up, Zika Is Gone, and Other ID Things to Be Grateful For, 2019 Edition

An excellent episode of the Freakonomics podcast introduced me to the headwinds vs tailwinds asymmetry, and how we humans perceive life. It goes like this: We go for a walk, a run, or a bike ride, and the wind faces us dead-on, making the exercise a struggle. (In windy Boston, the wind is always in my face. Always […]

---

November 11th, 2019

When TV Gets ID Wrong — Or At Least Not Quite Right

A busy week for Infectious Diseases on television! First, Dr. Aditya Shah, an ID doctor at Mayo Clinic, treated us to several snippets of truly idiotic ID-related drama in a network television show. After seeing them, I commented: Hey, my services to this show to help you talk about infectious diseases without sounding dumb are available at a […]

---

July 28th, 2019

Really Rapid Review — IAS 2019 Mexico City

As I noted last week — and you did read last week’s post, didn’t you? — the International AIDS conference first took place in Mexico City in 2008. Last week we returned to this sprawling, vibrant city for the 2019 meeting. It was an excellent, well-run conference — with one small complaint. But more on that later… […]

---

July 21st, 2019

AIDS Conference Returns to Mexico City, Where We Saw an Underrated, Great Advance in HIV Therapy

If you’ve been an ID or HIV specialist for only a decade or so, the following statement might seem unfathomable to you: Until 2008, there were lots of people with HIV whose medication adherence was perfect — but they still had virologic failure. How could that be? The simple answer is that their virus had too […]

---

May 5th, 2019

Latest Published Study on HIV Treatment as Prevention Is Déjà Vu All Over Again, But Some News Is So Good It Never Gets Old

Even if you’re not an ID or HIV specialist, there’s an excellent chance you’ve heard of the PARTNER2 study, just published in The Lancet. If not, the title could not be more descriptive: Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy And, in case you’ve just […]

---

March 24th, 2019

Tetanus Case, No More MAC Prophylaxis, Playing in Dirt, and Low-Level Viremia — A National Puppy Day ID Link-O-Rama

In honor of spring (March 20), and the very important National Puppy Day (March 23), here are a bunch of ID and HIV-related recent items for consideration, contemplation, and perusal: A life-threatening case of tetanus in an unvaccinated boy highlights the personal and financial cost of the anti-vaccine movement. How deeply embedded are these false beliefs? The […]

---

March 18th, 2019

Just 1 Month of TB Preventive Therapy Works for People with HIV in TB-Endemic Regions — How About Other People in Other Places?

There’s a look our patients frequently give us when we tell them that preventive therapy for tuberculosis involves 9 months of treatment. If I were to put that look into words, they would be: Yikes, Doc, 9 months is waaay too long — you must be out of your mind. It’s the “9 months?!?!” face. We’ve […]

---

March 10th, 2019

Really Rapid Review — CROI 2019 Seattle

As a foot of wet snow bore down on Boston last week — see this post for why that matters — HIV researchers and policy makers headed to Seattle for this year’s Conference on Retroviruses and Opportunistic Infections, or CROI, which took place from March 4-7. And already I was feeling the pressure, based on this […]

---

March 3rd, 2019

A Few Thoughts on the Day Before CROI — Our Best (and Quirkiest) Scientific Meeting

As I’ve written here numerous times, the Conference on Retroviruses and Opportunistic Infections — or “CROI” (rhymes with “toy”) — is the best of the scientific meetings on HIV. It starts March 4 in Seattle. Bringing together the perfect blend of clinical, translational, and epidemiologic research, CROI consistently boasts the highest density of worthwhile content in any […]

---

February 3rd, 2019

An “Interview” with the OVIVA Study of Oral vs. IV Antibiotics for Osteomyelitis

An “interview” inspired by publication of a landmark clinical trial. All responses written by me — but be assured, they are based on reading the paper, the accompanying editorial, the supplemental appendix, hundreds of comments on Twitter (some of them from the study investigators), and even a few generous comments from the the senior author in […]

---